Pfizer Competitors

Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Institutional and Insider Ownership

67.3% of Johnson & Johnson shares are held by institutional investors. Comparatively, 67.4% of Pfizer shares are held by institutional investors. 0.3% of Johnson & Johnson shares are held by company insiders. Comparatively, 0.1% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Johnson & Johnson has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.

Profitability

This table compares Johnson & Johnson and Pfizer's net margins, return on equity and return on assets.

Dividends

Johnson & Johnson pays an annual dividend of $4.04 per share and has a dividend yield of 2.5%. Pfizer pays an annual dividend of $1.52 per share and has a dividend yield of 4.2%. Johnson & Johnson pays out 46.5% of its earnings in the form of a dividend. Pfizer pays out 51.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has increased its dividend for 59 consecutive years and Pfizer has increased its dividend for 1 consecutive years.

Valuation & Earnings

This table compares Johnson & Johnson and Pfizer's gross revenue, earnings per share and valuation.

Pfizer has lower revenue, but higher earnings than Johnson & Johnson. Pfizer is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Johnson & Johnson and Pfizer, as reported by MarketBeat.com.

Johnson & Johnson currently has a consensus price target of $166.6923, indicating a potential upside of 1.92%. Pfizer has a consensus price target of $40.0714, indicating a potential upside of 9.63%. Given Pfizer's higher possible upside, analysts plainly believe Pfizer is more favorable than Johnson & Johnson.

Summary

Johnson & Johnson beats Pfizer on 12 of the 16 factors compared between the two stocks.

Merck & Co., Inc. (NYSE:MRK) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Institutional and Insider Ownership

72.9% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 67.4% of Pfizer shares are held by institutional investors. 0.3% of Merck & Co., Inc. shares are held by company insiders. Comparatively, 0.1% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Merck & Co., Inc. has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.

Profitability

This table compares Merck & Co., Inc. and Pfizer's net margins, return on equity and return on assets.

Dividends

Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.2%. Pfizer pays an annual dividend of $1.52 per share and has a dividend yield of 4.2%. Merck & Co., Inc. pays out 50.1% of its earnings in the form of a dividend. Pfizer pays out 51.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Merck & Co., Inc. has increased its dividend for 1 consecutive years and Pfizer has increased its dividend for 1 consecutive years.

Valuation & Earnings

This table compares Merck & Co., Inc. and Pfizer's gross revenue, earnings per share and valuation.

Pfizer has higher revenue and earnings than Merck & Co., Inc.. Pfizer is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Merck & Co., Inc. and Pfizer, as reported by MarketBeat.com.

Merck & Co., Inc. currently has a consensus price target of $95.3571, indicating a potential upside of 17.75%. Pfizer has a consensus price target of $40.0714, indicating a potential upside of 9.63%. Given Merck & Co., Inc.'s stronger consensus rating and higher possible upside, equities analysts plainly believe Merck & Co., Inc. is more favorable than Pfizer.

Summary

Merck & Co., Inc. beats Pfizer on 11 of the 16 factors compared between the two stocks.

Eli Lilly and (NYSE:LLY) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Institutional and Insider Ownership

75.6% of Eli Lilly and shares are held by institutional investors. Comparatively, 67.4% of Pfizer shares are held by institutional investors. 0.1% of Eli Lilly and shares are held by company insiders. Comparatively, 0.1% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Eli Lilly and has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.

Profitability

This table compares Eli Lilly and and Pfizer's net margins, return on equity and return on assets.

Dividends

Eli Lilly and pays an annual dividend of $2.96 per share and has a dividend yield of 1.4%. Pfizer pays an annual dividend of $1.52 per share and has a dividend yield of 4.2%. Eli Lilly and pays out 49.0% of its earnings in the form of a dividend. Pfizer pays out 51.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Eli Lilly and has increased its dividend for 1 consecutive years and Pfizer has increased its dividend for 1 consecutive years.

Valuation & Earnings

This table compares Eli Lilly and and Pfizer's gross revenue, earnings per share and valuation.

Pfizer has higher revenue and earnings than Eli Lilly and. Pfizer is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Eli Lilly and and Pfizer, as reported by MarketBeat.com.

Eli Lilly and currently has a consensus price target of $179.5714, indicating a potential downside of 12.89%. Pfizer has a consensus price target of $40.0714, indicating a potential upside of 9.63%. Given Pfizer's higher possible upside, analysts plainly believe Pfizer is more favorable than Eli Lilly and.

Summary

Eli Lilly and beats Pfizer on 12 of the 17 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Dividends

AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.7%. Pfizer pays an annual dividend of $1.52 per share and has a dividend yield of 4.2%. AbbVie pays out 58.2% of its earnings in the form of a dividend. Pfizer pays out 51.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has increased its dividend for 49 consecutive years and Pfizer has increased its dividend for 1 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Valuation & Earnings

This table compares AbbVie and Pfizer's gross revenue, earnings per share and valuation.

Pfizer has higher revenue and earnings than AbbVie. Pfizer is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

AbbVie has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.

Institutional and Insider Ownership

67.5% of AbbVie shares are held by institutional investors. Comparatively, 67.4% of Pfizer shares are held by institutional investors. 0.1% of AbbVie shares are held by company insiders. Comparatively, 0.1% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for AbbVie and Pfizer, as reported by MarketBeat.com.

AbbVie currently has a consensus price target of $112.50, indicating a potential upside of 1.48%. Pfizer has a consensus price target of $40.0714, indicating a potential upside of 9.63%. Given Pfizer's higher possible upside, analysts plainly believe Pfizer is more favorable than AbbVie.

Profitability

This table compares AbbVie and Pfizer's net margins, return on equity and return on assets.

Summary

AbbVie beats Pfizer on 12 of the 17 factors compared between the two stocks.

Pfizer (NYSE:PFE) and Bristol-Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation.

Dividends

Pfizer pays an annual dividend of $1.52 per share and has a dividend yield of 4.2%. Bristol-Myers Squibb pays an annual dividend of $1.96 per share and has a dividend yield of 3.0%. Pfizer pays out 51.5% of its earnings in the form of a dividend. Bristol-Myers Squibb pays out 41.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has increased its dividend for 1 consecutive years and Bristol-Myers Squibb has increased its dividend for 1 consecutive years.

Earnings and Valuation

This table compares Pfizer and Bristol-Myers Squibb's revenue, earnings per share (EPS) and valuation.

Pfizer has higher revenue and earnings than Bristol-Myers Squibb. Pfizer is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Pfizer has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.

Institutional and Insider Ownership

67.4% of Pfizer shares are owned by institutional investors. Comparatively, 72.4% of Bristol-Myers Squibb shares are owned by institutional investors. 0.1% of Pfizer shares are owned by company insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Pfizer and Bristol-Myers Squibb, as provided by MarketBeat.com.

Pfizer currently has a consensus target price of $40.0714, indicating a potential upside of 9.63%. Bristol-Myers Squibb has a consensus target price of $74.2667, indicating a potential upside of 15.04%. Given Bristol-Myers Squibb's stronger consensus rating and higher probable upside, analysts clearly believe Bristol-Myers Squibb is more favorable than Pfizer.

Profitability

This table compares Pfizer and Bristol-Myers Squibb's net margins, return on equity and return on assets.

Summary

Bristol-Myers Squibb beats Pfizer on 11 of the 17 factors compared between the two stocks.

Pfizer (NYSE:PFE) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation.

Dividends

Pfizer pays an annual dividend of $1.52 per share and has a dividend yield of 4.2%. Zoetis pays an annual dividend of $1.00 per share and has a dividend yield of 0.6%. Pfizer pays out 51.5% of its earnings in the form of a dividend. Zoetis pays out 27.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has increased its dividend for 1 consecutive years and Zoetis has increased its dividend for 1 consecutive years.

Earnings and Valuation

This table compares Pfizer and Zoetis' revenue, earnings per share (EPS) and valuation.

Pfizer has higher revenue and earnings than Zoetis. Pfizer is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Pfizer has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500.

Institutional and Insider Ownership

67.4% of Pfizer shares are owned by institutional investors. Comparatively, 92.5% of Zoetis shares are owned by institutional investors. 0.1% of Pfizer shares are owned by company insiders. Comparatively, 0.2% of Zoetis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Pfizer and Zoetis, as provided by MarketBeat.com.

Pfizer currently has a consensus target price of $40.0714, indicating a potential upside of 9.63%. Zoetis has a consensus target price of $161.1429, indicating a potential downside of 1.34%. Given Pfizer's higher probable upside, analysts clearly believe Pfizer is more favorable than Zoetis.

Profitability

This table compares Pfizer and Zoetis' net margins, return on equity and return on assets.

Summary

Zoetis beats Pfizer on 13 of the 17 factors compared between the two stocks.